Nuclear transport modulators and uses thereof

1. A compound of structural formula III:

or a pharmaceutically acceptable salt thereof, wherein:

R b is —C(O)NH 2 , and

R 2 is heteroaryl having 5 to 15 ring atoms, wherein: R 2 is optionally substituted with 1, 2 or 3 substituents independently selected from halogen, C 1 -C 4 alkyl, halo-C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 thioalkoxy, hydroxyl, amino, C 1 -C 4 alkylamino, C 1 -C 4 dialkylamino, sulfhydryl, cyano, C 6 aryl and heteroaryl having 5 or 6 ring atoms.

2. The compound of claim 1 , wherein R 2 is an optionally substituted 5-6-membered heteroaryl having 1, 2 or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.

3. The compound of claim 2 , wherein R 2 is an optionally substituted 5-membered heteroaryl having 1, 2 or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.

4. The compound of claim 3 , wherein R 2 is an optionally substituted pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, or oxadiazolyl.

5. The compound of claim 2 , wherein R 2 is an optionally substituted 6-membered heteroaryl having 1, 2 or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.

6. The compound of claim 5 , wherein R 2 is an optionally substituted pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl.

7. The compound of claim 1 , wherein R 1 is optionally substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, C 1 -C 4 alkyl, —CF 3 , amino and cyano.

8. A compound represented by any one of the following structural formulas:

or a pharmaceutically acceptable salt of any of the foregoing.

9. The compound of claim 8 , selected from:

or a pharmaceutically acceptable salt of any of the foregoing, wherein the exocyclic double bond is in a trans configuration.

10. The compound of claim 8 , selected from:

or a pharmaceutically acceptable salt of any of the foregoing, wherein the exocyclic double bond is in a cis configuration.

11. A pharmaceutically acceptable composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. A method for treating lymphoma, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by

or a pharmaceutically acceptable salt thereof.

13. The method according to claim 12 , wherein the lymphoma is non-Hodgkin's B-cell lymphoma.

14. The method according to claim 12 , wherein the lymphoma is selected from diffuse large B-cell lymphoma, Burkitt's lymphoma, cutaneous T-cell lymphoma, follicular lymphoma and mantle cell lymphoma.

15. A method for treating leukemia, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by

or a pharmaceutically acceptable salt thereof.

16. The method according to claim 15 , wherein the leukemia is selected from hairy cell leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, acute myeloid leukemia and chronic lymphocytic leukemia.

17. A method for treating a solid tumors, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by

or a pharmaceutically acceptable salt thereof, wherein the solid tumor is selected from prostate, breast, liver, colorectal, pancreatic, renal, osteosarcoma, lung, cervical and ovarian.

18. The method according to any one of claims 12 and 13 - 17 , wherein the compound is administered orally.

19. A pharmaceutically acceptable composition comprising a compound represented by

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.